Browse

You are looking at 101 - 110 of 3,328 items for

Full access

Kai-li Liang, Sean A. Tackett, Valerie Peterson, Tricia Patel, Michelle Turner, Sarah Sagorsky, Julie Brahmer, Christine Hann, Patrick Forde, Jarushka Naidoo, Kristen A. Marrone, David Ettinger, Ilene S. Browner, Vincent Lam, Russell K. Hales, Khinh R. Voong and Josephine L. Feliciano

Full access

Rebecca P. Luoh, Amye J. Tevaarwerk, Thevaa Chandereng, Elena M. Smith, Cibele Carroll, Hamid Emamekhoo and Mary E. Sesto

Full access

Mary Marasa, Elaine Bundy and Crystal DeVance-Wilson

Full access

Kathy Ruble, Juliana Pare-Blagoev, Lisa Carey, Kimberly Milla, Sydney Henegan, Clifton Thornton and Lisa Jacobson

Full access

Hassaan Yasin, Kemnasom Nwanwene, Mahmoud Abdallah, Todd Gress and Maria Tria Tirona

Full access

Prasanna J. Ananth, Sophia Mun, Noora Reffat, Soo Jung Kang, Sarah Pitafi, Xiaomei Ma, Cary P. Gross and Joanne Wolfe

Full access

P. Connor Johnson, Caron Jacobson, Alisha Yi, Anna Saucier, Tejaswini M. Dhawale, Ashley Nelson, Mitchell W. Lavoie, Mathew J. Reynolds, Carlisle E.W. Topping, Matthew J. Frigault and Areej El-Jawahri

Background: CAR T-cell therapy has revolutionized the treatment of patients with hematologic malignancies, but it can result in prolonged hospitalizations and serious toxicities. However, data on the impact of CAR T-cell therapy on healthcare utilization and end-of-life (EoL) outcomes are lacking. Methods: We conducted a retrospective analysis of 236 patients who received CAR T-cell therapy at 2 tertiary care centers from February 2016 through December 2019. We abstracted healthcare utilization and EoL outcomes from the electronic health record, including hospitalizations, receipt of ICU care, hospitalization and receipt of systemic therapy in the last 30 days of life, palliative care, and hospice referrals. Results: Most patients (81.4%; n=192) received axicabtagene ciloleucel. Overall, 28.1% of patients experienced a hospital readmission and 15.5% required admission to the ICU within 3 months of CAR T-cell therapy. Among the deceased cohort, 58.3% (49/84) were hospitalized and 32.5% (26/80) received systemic therapy in the last 30 days of life. Rates of palliative care and hospice referrals were 47.6% and 30.9%, respectively. In multivariable logistic regression, receipt of bridging therapy (odds ratio [OR], 3.15; P=.041), index CAR-T hospitalization length of stay >14 days (OR, 4.76; P=.009), hospital admission within 3 months of CAR T-cell infusion (OR, 4.29; P=.013), and indolent lymphoma transformed to diffuse large B-cell lymphoma (OR, 9.83; P=.012) were associated with likelihood of hospitalization in the last 30 days of life. Conclusions: A substantial minority of patients receiving CAR T-cell therapy experienced hospital readmission or ICU utilization in the first 3 months after CAR T-cell therapy, and most deceased recipients of CAR T-cell therapy received intensive EoL care. These findings underscore the need for interventions to optimize healthcare delivery and EoL care for this population.